Switch to:
Also traded in: Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.02
SHPG's Cash to Debt is ranked lower than
99% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. SHPG: 0.02 )
Ranked among companies with meaningful Cash to Debt only.
SHPG' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 1.44 Max: No Debt
Current: 0.02
Equity to Asset 0.55
SHPG's Equity to Asset is ranked lower than
64% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SHPG: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
SHPG' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.62 Max: 0.85
Current: 0.55
0.25
0.85
Interest Coverage 42.12
SHPG's Interest Coverage is ranked lower than
82% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 42.12 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s Interest Coverage Range Over the Past 10 Years
Min: 2.96  Med: 24.99 Max: 55.13
Current: 42.12
2.96
55.13
F-Score: 6
Z-Score: 4.03
M-Score: -2.91
WACC vs ROIC
13.92%
16.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 24.68
SHPG's Operating margin (%) is ranked higher than
88% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. SHPG: 24.68 )
Ranked among companies with meaningful Operating margin (%) only.
SHPG' s Operating margin (%) Range Over the Past 10 Years
Min: -56.61  Med: 21.75 Max: 35.13
Current: 24.68
-56.61
35.13
Net-margin (%) 50.48
SHPG's Net-margin (%) is ranked higher than
96% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. SHPG: 50.48 )
Ranked among companies with meaningful Net-margin (%) only.
SHPG' s Net-margin (%) Range Over the Past 10 Years
Min: -59.59  Med: 15.92 Max: 56.55
Current: 50.48
-59.59
56.55
ROE (%) 37.27
SHPG's ROE (%) is ranked higher than
97% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. SHPG: 37.27 )
Ranked among companies with meaningful ROE (%) only.
SHPG' s ROE (%) Range Over the Past 10 Years
Min: -90.17  Med: 17.82 Max: 49.38
Current: 37.27
-90.17
49.38
ROA (%) 20.63
SHPG's ROA (%) is ranked higher than
97% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. SHPG: 20.63 )
Ranked among companies with meaningful ROA (%) only.
SHPG' s ROA (%) Range Over the Past 10 Years
Min: -37.5  Med: 9.76 Max: 31.55
Current: 20.63
-37.5
31.55
ROC (Joel Greenblatt) (%) 291.49
SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. SHPG: 291.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -396.76  Med: 102.56 Max: 345.44
Current: 291.49
-396.76
345.44
Revenue Growth (3Y)(%) 12.40
SHPG's Revenue Growth (3Y)(%) is ranked higher than
69% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. SHPG: 12.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.7  Med: 12.10 Max: 26.8
Current: 12.4
-0.7
26.8
EBITDA Growth (3Y)(%) 38.70
SHPG's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. SHPG: 38.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.4  Med: 22.80 Max: 38.7
Current: 38.7
-1.4
38.7
EPS Growth (3Y)(%) 56.20
SHPG's EPS Growth (3Y)(%) is ranked higher than
93% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SHPG: 56.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.3  Med: 32.00 Max: 63.3
Current: 56.2
-7.3
63.3
» SHPG's 10-Y Financials

Financials (Next Earnings Date: 2016-02-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SHPG Guru Trades in Q1 2015

Steven Cohen 4,600 sh (New)
Jim Simons 197,512 sh (New)
First Eagle Investment 294,539 sh (+254.93%)
Leon Cooperman 500,192 sh (+5.70%)
Pioneer Investments 116,323 sh (+5.31%)
Ken Fisher 14,791 sh (+1.35%)
Murray Stahl 6,000 sh (unchged)
John Paulson 8,328,304 sh (unchged)
Andreas Halvorsen Sold Out
Daniel Loeb Sold Out
Mario Gabelli Sold Out
Louis Moore Bacon 20,000 sh (-66.27%)
» More
Q2 2015

SHPG Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 786,159 sh (New)
Ken Fisher 20,161 sh (+36.31%)
Jim Simons 264,812 sh (+34.07%)
Murray Stahl 6,000 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Leon Cooperman 496,192 sh (-0.80%)
John Paulson 7,095,100 sh (-14.81%)
Pioneer Investments 75,972 sh (-34.69%)
First Eagle Investment 4,830 sh (-98.36%)
» More
Q3 2015

SHPG Guru Trades in Q3 2015

Steven Cohen 100 sh (New)
Ken Fisher 31,064 sh (+54.08%)
Manning & Napier Advisors, Inc 786,159 sh (unchged)
First Eagle Investment 4,830 sh (unchged)
Murray Stahl 6,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
John Paulson 6,805,200 sh (-4.09%)
Jim Simons 225,712 sh (-14.77%)
Pioneer Investments 12,019 sh (-84.18%)
Leon Cooperman 45,367 sh (-90.86%)
» More
Q4 2015

SHPG Guru Trades in Q4 2015

Ken Fisher 33,954 sh (+9.30%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Shire PLC

John Paulson Sells Stake in Broadcom, Cuts Cablevision Holding A look at Paulson's 3rd quarter sales
John Paulson (Trades, Portfolio) is the president and portfolio manager of Paulson & Co. Inc. Paulson was ranked by Absolute Return Magazine as the third-largest hedge fund in the world, managing approximately $29 billion and focusing on merger, event and distressed strategies. Read more...
Manning & Napier's Top 5 New Stock Buys of Q2
Fund manager Manning & Napier purchased 61 new stocks across its portfolios in the second quarter. Read more...
Manning & Napier Invests in Stake in Baidu
In the first decade of the 21st century, Manning & Napier was the only investment manager to beat the S&P500 every year. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 10.50
SHPG's P/E(ttm) is ranked higher than
86% of the 376 Companies
in the Global Biotechnology industry.

( Industry Median: 30.34 vs. SHPG: 10.50 )
Ranked among companies with meaningful P/E(ttm) only.
SHPG' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 25.18 Max: 74.35
Current: 10.5
10.5
74.35
Forward P/E 10.91
SHPG's Forward P/E is ranked higher than
73% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.89 vs. SHPG: 10.91 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 11.03
SHPG's PE(NRI) is ranked higher than
84% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 31.50 vs. SHPG: 11.03 )
Ranked among companies with meaningful PE(NRI) only.
SHPG' s PE(NRI) Range Over the Past 10 Years
Min: 11.03  Med: 22.97 Max: 106.93
Current: 11.03
11.03
106.93
P/B 3.51
SHPG's P/B is ranked lower than
65% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. SHPG: 3.51 )
Ranked among companies with meaningful P/B only.
SHPG' s P/B Range Over the Past 10 Years
Min: 2.22  Med: 5.49 Max: 14.23
Current: 3.51
2.22
14.23
P/S 4.95
SHPG's P/S is ranked higher than
69% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. SHPG: 4.95 )
Ranked among companies with meaningful P/S only.
SHPG' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 4.44 Max: 9.28
Current: 4.95
2.25
9.28
PFCF 9.64
SHPG's PFCF is ranked higher than
87% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.21 vs. SHPG: 9.64 )
Ranked among companies with meaningful PFCF only.
SHPG' s PFCF Range Over the Past 10 Years
Min: 9.64  Med: 23.23 Max: 44
Current: 9.64
9.64
44
POCF 8.12
SHPG's POCF is ranked higher than
88% of the 383 Companies
in the Global Biotechnology industry.

( Industry Median: 28.02 vs. SHPG: 8.12 )
Ranked among companies with meaningful POCF only.
SHPG' s POCF Range Over the Past 10 Years
Min: 7.59  Med: 16.32 Max: 26.82
Current: 8.12
7.59
26.82
EV-to-EBIT 11.23
SHPG's EV-to-EBIT is ranked higher than
67% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. SHPG: 11.23 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 15.85 Max: 42.6
Current: 11.23
-16.1
42.6
EV-to-EBITDA 9.50
SHPG's EV-to-EBITDA is ranked higher than
69% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. SHPG: 9.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.3  Med: 12.60 Max: 28.6
Current: 9.5
-21.3
28.6
PEG 0.43
SHPG's PEG is ranked higher than
93% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.61 vs. SHPG: 0.43 )
Ranked among companies with meaningful PEG only.
SHPG' s PEG Range Over the Past 10 Years
Min: 0.39  Med: 1.07 Max: 1.83
Current: 0.43
0.39
1.83
Shiller P/E 47.78
SHPG's Shiller P/E is ranked higher than
58% of the 74 Companies
in the Global Biotechnology industry.

( Industry Median: 52.26 vs. SHPG: 47.78 )
Ranked among companies with meaningful Shiller P/E only.
SHPG' s Shiller P/E Range Over the Past 10 Years
Min: 47.78  Med: 113.40 Max: 469
Current: 47.78
47.78
469
Current Ratio 0.63
SHPG's Current Ratio is ranked lower than
93% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. SHPG: 0.63 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.76 Max: 7.43
Current: 0.63
0.52
7.43
Quick Ratio 0.49
SHPG's Quick Ratio is ranked lower than
92% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. SHPG: 0.49 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.53 Max: 7.07
Current: 0.49
0.4
7.07
Days Inventory 225.37
SHPG's Days Inventory is ranked lower than
76% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 124.17 vs. SHPG: 225.37 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 181.33 Max: 245.83
Current: 225.37
126.5
245.83
Days Sales Outstanding 75.56
SHPG's Days Sales Outstanding is ranked lower than
58% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. SHPG: 75.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 68.78 Max: 75.29
Current: 75.56
47.71
75.29
Days Payable 122.26
SHPG's Days Payable is ranked higher than
73% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 57.61 vs. SHPG: 122.26 )
Ranked among companies with meaningful Days Payable only.
SHPG' s Days Payable Range Over the Past 10 Years
Min: 80.31  Med: 110.24 Max: 161.12
Current: 122.26
80.31
161.12

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.44
SHPG's Dividend Yield is ranked lower than
87% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. SHPG: 0.44 )
Ranked among companies with meaningful Dividend Yield only.
SHPG' s Dividend Yield Range Over the Past 10 Years
Min: 0.23  Med: 0.42 Max: 0.7
Current: 0.44
0.23
0.7
Dividend Payout 0.05
SHPG's Dividend Payout is ranked higher than
99% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. SHPG: 0.05 )
Ranked among companies with meaningful Dividend Payout only.
SHPG' s Dividend Payout Range Over the Past 10 Years
Min: 0.05  Med: 0.25 Max: 1.23
Current: 0.05
0.05
1.23
Dividend Growth (3y) 16.00
SHPG's Dividend Growth (3y) is ranked higher than
77% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. SHPG: 16.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SHPG' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 13.45 Max: 57.9
Current: 16
0
57.9
Forward Dividend Yield 0.16
SHPG's Forward Dividend Yield is ranked lower than
88% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. SHPG: 0.16 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.92
SHPG's Yield on cost (5-Year) is ranked lower than
70% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. SHPG: 0.92 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPG' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.49  Med: 0.90 Max: 1.5
Current: 0.92
0.49
1.5
3-Year Average Share Buyback Ratio 0.20
SHPG's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 531 Companies
in the Global Biotechnology industry.

( Industry Median: -9.90 vs. SHPG: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.8  Med: -2.60 Max: 1.4
Current: 0.2
-28.8
1.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.12
SHPG's Price/Projected FCF is ranked higher than
88% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 3.23 vs. SHPG: 1.12 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.13  Med: 1.68 Max: 2.65
Current: 1.12
1.13
2.65
Price/Median PS Value 1.13
SHPG's Price/Median PS Value is ranked lower than
63% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 1.13 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 0.97 Max: 2.86
Current: 1.13
0.55
2.86
Price/Peter Lynch Fair Value 0.41
SHPG's Price/Peter Lynch Fair Value is ranked higher than
95% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 1.76 vs. SHPG: 0.41 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.54  Med: 1.27 Max: 2.92
Current: 0.41
0.54
2.92
Earnings Yield (Greenblatt) (%) 8.92
SHPG's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. SHPG: 8.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 5.90 Max: 9.3
Current: 8.92
2.3
9.3
Forward Rate of Return (Yacktman) (%) 33.00
SHPG's Forward Rate of Return (Yacktman) (%) is ranked higher than
83% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.48 vs. SHPG: 33.00 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 2.40 Max: 33.5
Current: 33
1.5
33.5

More Statistics

Revenue(Mil) $6298
EPS $ 16.24
Beta1.36
Short Percentage of Float1.98%
52-Week Range $156.42 - 270.63
Shares Outstanding(Mil)200.20

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 6,189 6,873 7,542 8,951
EPS($) 12.21 13.79 14.42 18.24
EPS without NRI($) 12.21 13.79 14.42 18.24

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:S7E.Germany, SHPG N.Mexico, SHP.UK, SHPGF.USA,
Shire PLC was registered in Jersey on 28th January, 2008. It is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs. The Company unified its business during 2013 by integrating the operations of the Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT) and Regenerative Medicine (RM) business units into a simplified One Shire organization. The Company has four commercial units that focus exclusively on the commercial execution of its In-Line products in the following specialist therapeutic areas: Rare Diseases, Neuroscience, Gastrointestinal (GI) and Internal Medicine. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the US, the EU and other territories.
» More Articles for SHPG

Headlines

Articles On GuruFocus.com
Tweedy Browne Fund 4th Quarter Commentary Jan 27 2016 
John Paulson Sells Stake in Broadcom, Cuts Cablevision Holding Nov 18 2015 
Undervalued Baxalta Shares Target of Acquisition by Shire Plc Aug 05 2015 
Manning & Napier's Top 5 New Stock Buys of Q2 Jul 09 2015 
Manning & Napier Invests in Stake in Baidu Jul 08 2015 
Invesco European Growth Fund Parts With Two Stakes Jul 01 2015 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
John Paulson's Stocks Trading at Low P/E May 04 2015 

More From Other Websites
Shire's NDA Resubmission for Lifitegrast Accepted by FDA Feb 05 2016
Momentum, Strategy within Today's Market - Analyst Notes on AmerisourceBergen, Xcel Energy, Shire... Feb 05 2016
3:48 pm Shire plc: FDA acknowledges receipt of the resubmitted NDA for lifitegrast for the treatment... Feb 04 2016
U.S. FDA Acknowledges Receipt of Resubmission of Shire's New Drug Application for Lifitegrast for... Feb 04 2016
Drug Manufacturers - Major Equities Technical Updates -- TherapeuticsMD, Sanofi, Shire, and Novartis Feb 04 2016
Will AmerisourceBergen's (ABC) Q1 Earnings Disappoint? Feb 03 2016
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Feb 03 2016
Headline Risk Is Poison for Pharma and Biotech Feb 03 2016
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Feb 01 2016
Total Voting Rights Feb 01 2016
AbbVie cuts costs, turns profit that meets 4Q expectations Jan 29 2016
SHIRE PLC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and... Jan 28 2016
Pharma firm gets FDA approval for ADHD drug, more jobs likely Jan 28 2016
Shire PLC assigned investment grade ... Jan 28 2016
Shire plc Assigned Investment Grade Credit Ratings by Moody's and S&P Jan 28 2016
Shire to announce Full Year 2015 ... Jan 28 2016
Shire plc -- Moody's assigns Baa3 issuer rating to Shire plc; stable outlook Jan 28 2016
The Baxalta–Shire merger: Basics of Shire Pharmaceuticals Jan 26 2016
Shire stays mum on Burlington facilities, employees in wake of Dyax acquisition Jan 25 2016
Shire Resubmits New Drug Application ... Jan 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK